[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insight Molecular Diagnostics Inc (IMDX)

Insight Molecular Diagnostics Inc (IMDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 141,368
  • Shares Outstanding, K 32,724
  • Annual Sales, $ 4,060 K
  • Annual Income, $ -50,220 K
  • EBIT $ -49 M
  • EBITDA $ -47 M
  • 60-Month Beta 1.79
  • Price/Sales 29.94
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 289.47% (-365.39%)
  • Historical Volatility 100.85%
  • IV Percentile 22%
  • IV Rank 21.37%
  • IV High 1,191.63% on 03/11/26
  • IV Low 44.23% on 03/12/26
  • Expected Move (DTE 5) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 101
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 976
  • Open Int (30-Day) 666
  • Expected Range 4.32 to 4.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.48
  • Growth Rate Est. (year over year) +208,025.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.54 +22.03%
on 08/13/26
5.32 -18.80%
on 08/04/26
-0.14 (-3.14%)
since 07/14/26
3-Month
3.54 +22.03%
on 08/13/26
6.86 -37.03%
on 05/18/26
-2.10 (-32.71%)
since 05/14/26
52-Week
2.33 +85.41%
on 08/29/25
8.51 -49.24%
on 11/12/25
+1.92 (+80.00%)
since 08/14/25

Most Recent Stories

More News
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing

NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August...

IMDX : 4.32 (+16.44%)
Insight Molecular Diagnostics: Q2 Earnings Snapshot

Insight Molecular Diagnostics: Q2 Earnings Snapshot

IMDX : 4.32 (+16.44%)
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

Discussions with FDA advance toward expected marketing authorization for GraftAssureDx FDA completes current portion of substantive review in a timely manner Favorable Medicare reimbursement policy issued...

BIO : 356.26 (-1.36%)
IMDX : 4.32 (+16.44%)
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference

NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market...

IMDX : 4.32 (+16.44%)
iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication

Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection Serial monitoring of patients through donor-derived cell-free...

IMDX : 4.32 (+16.44%)
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing Supports iMDx's commercial strategy in transplant monitoring Final policy establishes recurring testing...

IMDX : 4.32 (+16.44%)
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of molecular...

IMDX : 4.32 (+16.44%)
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation - NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics...

IMDX : 4.32 (+16.44%)
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor GraftAssure’s industry-leading reference change value (time-point...

IMDX : 4.32 (+16.44%)
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone GraftAssure™ assay doubles reliability...

IMDX : 4.32 (+16.44%)

Business Summary

Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 5.13
2nd Resistance Point 4.75
1st Resistance Point 4.53
Last Price 4.32
1st Support Level 3.93
2nd Support Level 3.55
3rd Support Level 3.33

See More

52-Week High 8.51
Fibonacci 61.8% 6.15
Fibonacci 50% 5.42
Fibonacci 38.2% 4.69
Last Price 4.32
52-Week Low 2.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.